Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
64Cu-FAPI-XT117 PET/CT in Malignant Solid Tumors
NCT05930457Phase 1Completed
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Jul 2023
- Primary completion
- Oct 2023
- Modality
- Diagnostic, Positron Emission Tomography Imaging
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 64Cu-FAPI-XT117 in malignant solid tumor, sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 7 days. Started Jul 2023; status: completed.
02
Drugs
64Cu-FAPI-XT117
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT05930457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930457.